Iloperidone

• Schizophrenia
• Psychosis
• Antipsychotic Therapy
• Mental Health Treatment

Iloperidone (Fanapt) is an oral atypical antipsychotic approved for the treatment of schizophrenia in adults. It belongs to the second-generation class alongside agents such as risperidone, paliperidone, and lurasidone, and is differentiated by its receptor profile and the requirement for slow titration. The trade-off built into iloperidone is well defined: a lower risk of movement disorders and modest metabolic effects on one side, and a multi-day titration to reach a therapeutic dose on the other. That makes it most useful for outpatient management of stable or partially stable patients rather than for acute crisis intervention where rapid symptom control is required.

Mechanism of Action

Iloperidone is a piperidinyl-benzisoxazole derivative that binds with high affinity to dopamine D2 and D3 receptors, serotonin 5-HT2A receptors, and norepinephrine alpha-1 adrenergic receptors. The combined antagonism of D2 and 5-HT2A receptors is the central explanation for its antipsychotic activity. Blocking D2 receptors in mesolimbic pathways reduces the positive symptoms of schizophrenia such as delusions, hallucinations, and disorganized thought. Blocking 5-HT2A receptors enhances dopamine release in the prefrontal cortex, which is thought to mitigate negative symptoms and reduce the extrapyramidal side effects that pure D2 blockade would otherwise produce. The high binding affinity to 5-HT2A relative to D2 places iloperidone in the same favorable EPS profile as several other atypicals.

The high alpha-1 adrenergic antagonism explains why titration matters so much. Alpha-1 blockade in vascular smooth muscle dilates arterioles and predisposes to orthostatic hypotension, dizziness, and reflex tachycardia, particularly during the first days of treatment before baroreceptor adaptation occurs. Iloperidone also has modest H1 histamine and muscarinic receptor activity, which contributes to mild sedation and dry mouth but produces less anticholinergic burden than older agents. The drug is metabolized primarily by CYP2D6 and CYP3A4, so genetic poor metabolizer status or coadministration of strong inhibitors of those enzymes substantially raises plasma concentrations and the risk of QT prolongation. The two main metabolites P88 and P95 contribute to overall pharmacologic effect and prolong the effective duration of action. Patients and families can find background on antipsychotic medications at NIMH and on serious mental illness from SAMHSA.

Clinical Use

Within the schizophrenia treatment algorithm, second-generation antipsychotics are typically chosen as first-line therapy because they cause fewer extrapyramidal symptoms than older agents such as haloperidol. Within that group iloperidone occupies a niche for patients who have not tolerated other atypicals, particularly those who developed akathisia, dystonia, or tardive dyskinesia, or for those whose metabolic profiles cannot accommodate olanzapine or quetiapine. It is generally not the agent reached for first when rapid symptom control is needed, because the slow titration delays full effect for one to two weeks. Long-acting injectable antipsychotics or aripiprazole are usually preferred when adherence is a primary concern.

Clinical trials measured efficacy using the Positive and Negative Syndrome Scale (PANSS) and demonstrated improvement comparable to haloperidol and risperidone, with a more favorable extrapyramidal profile. Weight gain is moderate, generally falling between aripiprazole on the lower end and olanzapine on the higher end. Iloperidone does prolong the QT interval to a clinically meaningful degree, which influences patient selection. It is well suited to a stable outpatient with persistent symptoms, normal baseline EKG, no concurrent QT-prolonging medications, and willingness to tolerate a structured up-titration. It is poorly suited to patients with cardiovascular comorbidity, frail older adults, or anyone in whom adherence to a daily pill is uncertain. Comparative effectiveness data show iloperidone produces antipsychotic response in roughly 50 to 60 percent of patients within 6 weeks, similar to other atypicals. The combination of CYP2D6 metabolism, dose-dependent QT effects, and titration requirement means that the patient-clinician relationship and reliable follow-up access matter as much as drug selection itself. Coordinating care between psychiatry and primary care is particularly valuable here.

How to Take It

Iloperidone is taken twice daily with or without food. The mandatory titration schedule begins with 1 mg twice daily on day one, increasing by 2 mg per dose each day until reaching the target of 6 to 12 mg twice daily — a total of 12 to 24 mg per day. Maximum dose is 12 mg twice daily. Patients should expect to reach an effective dose around day seven, with full therapeutic benefit emerging over the following one to two weeks. If treatment is interrupted for more than three days, the entire titration should be repeated to avoid orthostatic episodes. Missed doses should be taken when remembered if it is close to the scheduled time; otherwise the missed dose is skipped. Tablets are stored at room temperature in the original container. During the first week patients often experience dizziness, nasal congestion, mild somnolence, or dry mouth. Rising slowly from sitting and avoiding alcohol during the first two weeks reduces falls. Adequate hydration also helps blunt the orthostatic effect, and patients should be cautioned about driving or operating machinery until tolerance is established.

Monitoring and Follow-Up

Baseline assessment includes weight, height, BMI, waist circumference, blood pressure, fasting glucose or A1c, fasting lipid panel, prolactin if symptomatic, and a 12-lead EKG to document the QT interval. The EKG is repeated after dose stabilization and any time a QT-prolonging medication is added. Weight and blood pressure are checked at each visit during titration, then quarterly. Fasting glucose and lipids are repeated at three months and then annually unless abnormalities require closer follow-up. Movement disorder screens such as the Abnormal Involuntary Movement Scale are performed at baseline and every six months to detect early tardive dyskinesia. Numbers worth alarm include a corrected QT above 500 ms or a rise of more than 60 ms from baseline, weight gain exceeding 7 percent of body weight, fasting glucose above 126 mg/dL, or LDL above 160 mg/dL. Prolactin elevation that produces galactorrhea, sexual dysfunction, or menstrual changes also warrants reassessment. Any episode of syncope deserves an EKG and electrolyte review. Periodic CBC monitoring is reasonable because of the small risk of leukopenia and neutropenia, particularly during the first months.

Special Populations

Iloperidone is not indicated for elderly patients with dementia-related psychosis because of increased mortality, a class-wide boxed warning. Pregnancy data are limited; neonates exposed in the third trimester may experience withdrawal or extrapyramidal symptoms, and use should reflect a careful risk-benefit discussion. Breastfeeding is generally not recommended. Safety and efficacy have not been established in pediatric patients. Older adults are more sensitive to orthostatic hypotension and falls and should be titrated even more cautiously, often to lower target doses. Patients identified as CYP2D6 poor metabolizers, or those taking strong CYP2D6 or CYP3A4 inhibitors such as paroxetine, fluoxetine, or ketoconazole, require a 50 percent dose reduction. Hepatic impairment is a contraindication for use because of the absence of safety data. Renal impairment does not require dose adjustment. Patients with seizure history warrant lower doses and slower titration. Smoking induces CYP1A2 but is not the primary metabolic pathway, so smoking cessation does not require dose change as it does with some other antipsychotics. The FDA prescribing information is the definitive reference for boxed warnings and contraindications.

When to Contact Your Doctor

Call immediately for fainting, palpitations, or chest pain — these may signal QT prolongation or arrhythmia. High fever with muscle rigidity, confusion, and unstable vital signs may indicate neuroleptic malignant syndrome and is a medical emergency. New uncontrollable movements of the face, tongue, or limbs can be early tardive dyskinesia. Persistent dizziness or fainting on standing, especially after a missed dose or restart, deserves prompt review. Worsening psychiatric symptoms, suicidal thoughts, severe agitation, or a return of hallucinations should be reported the same day. Signs of infection along with sore throat or fatigue may reflect rare neutropenia. Significant weight gain, increased thirst, or blurry vision can mark new metabolic problems. Painful or prolonged erection in male patients is a urologic emergency requiring immediate care.

If you or a family member would benefit from coordinated management of schizophrenia and overall medical health, contact us or schedule a visit at our St. Petersburg practice to align medication and primary care.